Balyasny Asset Management
NTLA icon

Balyasny Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Balyasny Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.17M Buy
+169,286
New +$2.16M ﹤0.01% 1742
2025
Q4 		– Sell
-255,555
Closed -$4.41M – 3407
2025
Q3 		$4.41M Sell
255,555
-1,055,925
-81% -$13M 0.01% 1420
2025
Q2 		$12.3M Sell
1,311,480
-203,605
-13% -$1.67M 0.02% 876
2025
Q1 		$10.8M Sell
1,515,085
-791,209
-34% -$7.99M 0.02% 877
2024
Q4 		$26.9M Buy
2,306,294
+1,556,433
+208% +$24.3M 0.04% 536
2024
Q3 		$15.4M Buy
749,861
+402,378
+116% +$9.28M 0.03% 746
2024
Q2 		$7.78M Buy
347,483
+158,982
+84% +$3.79M 0.01% 990
2024
Q1 		$5.19M Buy
+188,501
New +$5.24M 0.01% 1205
2023
Q1 		– Sell
-762
Closed -$26.6K – 2994
2022
Q4 		$26.6K Sell
762
-38,927
-98% -$1.85M ﹤0.01% 2447
2022
Q3 		$2.22M Buy
+39,689
New +$2.46M 0.01% 1437
2021
Q2 		– Sell
-38,720
Closed -$3.11M – 2231
2021
Q1 		$3.11M Sell
38,720
-44,473
-53% -$2.99M 0.02% 872
2020
Q4 		$4.53M Buy
+83,193
New +$3.02M 0.03% 679
2019
Q3 		– Sell
-57,321
Closed -$938K – 1452
2019
Q2 		$938K Buy
57,321
+11,675
+26% +$184K 0.01% 1094
2019
Q1 		$780K Sell
45,646
-1,265
-3% -$18.9K 0.01% 1086
2018
Q4 		$640K Buy
+46,911
New +$872K ﹤0.01% 1032

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Balyasny Asset Management's NTLA Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 169,286 shares worth $2.17M. The stake represents ﹤0.01% of the portfolio and ranks #1742 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in NTLA as recently as Q3 2025.

Balyasny Asset Management first reported a position in NTLA in Q4 2018 and has held it in 15 quarters since. The position peaked at $26.9M in Q4 2024. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Balyasny Asset Management held 169,286 shares of Intellia Therapeutics worth $2.17M as of Q1 2026.
  • Intellia Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1742 holding.
  • Balyasny Asset Management first reported a position in Intellia Therapeutics in Q4 2018 and has held it in 15 quarters since.
  • Balyasny Asset Management's Intellia Therapeutics position peaked at $26.9M in Q4 2024.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.